Cash Flow Statement

Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Cash Change in Intangibles Change in Working Capital Exchange Rate Effect Free Cash Flow Long-Term Debt Repayments Net Cash Flow Net Income Sales of Property, Plant and Equipment

Daily Values

Growth Metrics

Others

Ratios

Innate Pharma (IPHA) Gains from Investment Securities (2023)

Historic Gains from Investment Securities for Innate Pharma (IPHA) over the last 1 years, with Q2 2023 value amounting to -$1.1 million.